Companies ›Healthcare ›6649.TWO

6649.TWO — TPEx Medical Equipment, Supplies & Distribution

Taiwan Biomaterial Co Ltd

$39,25

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

2,47 %

Op margin

27,6 %

ROE

8,6 %

Net margin

26,7 %

Debt / equity

0,08

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Taiwan Biomaterial Co Ltd develops and distributes medical equipment and supplies, primarily serving the healthcare sector.

Business. Taiwan Biomaterial Co Ltd (6649.TWO) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Headquartered in Taiwan, the company is primarily listed on the Taiwan Premium Exchange (TPEx).

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryMedical Equipment, Supplies & Distribution

ActivityHealthcare Services & Equipment

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

8,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 6649.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 6649.TWO. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Taiwan Biomaterial Co Ltd (6649.TWO) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Headquartered in Taiwan, the company is primarily listed on the Taiwan Premium Exchange (TPEx).

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryMedical Equipment, Supplies & Distribution

ActivityHealthcare Services & Equipment

AI synthesis

GENERATED

Taiwan Biomaterial Co Ltd maintains a strong liquidity position, with a current ratio of 8.53 and cash and equivalents amounting to TWD 258.4 million. The company's debt-to-equity ratio is 0.08, indicating a conservative capital structure with minimal leverage. Free cash flow of TWD 76.98 million and operating cash flow of TWD 48.77 million further support its liquidity profile.

The company's profitability is reflected in a return on equity (ROE) of 8.6% and a return on assets (ROA) of 7.46%. These metrics are in line with the industry's preferred focus on asset efficiency and capital returns. Gross profit of TWD 134.8 million and operating income of TWD 60.83 million suggest a healthy margin structure.

The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic diversification data available in the current dataset. This lack of diversification may expose the company to regional or sector-specific risks.

Outlook data indicates a stable growth trajectory, with no significant revenue changes expected in the current or next fiscal year. Historical revenue of TWD 220.4 million provides a baseline for future performance. Capital expenditure of TWD -3.14 million suggests minimal investment in new assets, which may limit future growth unless offset by organic expansion.

Risk assessment shows low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong cash position reduce financial stressors. No dilution pressure is expected in the near term, as shares outstanding remain unchanged between basic and diluted counts.

Recent filings and transcripts do not indicate any material events or strategic shifts. The company appears to be operating within a stable and predictable framework, with no disclosed regulatory or operational disruptions.

Key takeaways

Strong liquidity and low leverage support financial stability.
ROE and ROA are in line with industry expectations for asset efficiency.
Revenue concentration in a single segment may increase exposure to sector-specific risks.
Minimal capital expenditure suggests a conservative approach to growth.
No immediate dilution or liquidity risks are present.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$39,25

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$685.1M

Net cashⓘ

$205.8M

Current ratioⓘ

8.5

Debt / equityⓘ

0.1

ROAⓘ

7.5%

ROEⓘ

8.6%

Cash conversionⓘ

83.0%

CapEx / revenueⓘ

-1.4%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin27,6 %Above P75

Net Margin26,7 %Best in class

ROE8,6 %Above P75

Capex / Rev-1,4 %Above P75

D/E0,08Above median

Cash Conv0,83Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Taiwan Biomaterial Co Ltd Market data — financials · 2026-05-27

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

6649.TWOCanonical

TPEx · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread